LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

Post-LOE

losartan potassium and hydrochlorothiazide

Jubilant Therapeutics

ANDAORALTABLET

Approved

Nov 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (losartan potassium and hydrochlorothiazide) by Jubilant Therapeutics is 12. Approved for hypertension, to lower blood pressure, the risk of stroke in patients with hypertension and 4 more indications. First approved in 2017.

Drug data last refreshed 21h ago

Mechanism of Action

12.1 Mechanism of Action Losartan Potassium Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the…

Worked on LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

Mechanism of Action

Indications (6)